Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Wakey wakey we have some volume here today at last. Something afoot?
Meant to be starting clinical trials within weeks. Worst-case seems to be a delay to these starting.
As you say the SP may continue its malaise without news but with £8-9m cash in the bank and Juv royalties on the way from next year the downside seems limited.
Anyone who has held through the last 1-2 years must surely have the patience to see this out now, or so you'd think.
Disappointing, is any news imminent?
Bad news I can live with and trade.
No news and sp stasi or slow decline is a drag.
Also take a look at the following which is part of a presentation from Juvenescence earlier this year and suggests a H1 launch:
Https://youtu.be/SJ6UT0Kj62w?t=1141
Thanks Ontarget, catching up on chats been busy will check the link out
Btw you can sign up to get emails from Juvlife at the bottom of this page: https://www.juvlabs.com/organization/division/juvlife might be useful to spot any early signs of marketing
Meanwhile we await news on these two clinical trials that are supposedly starting in Q4 this year (less than 1 month away).
Heard both H1 and H2 next year for the launch, so kicking off some time next year.
Hi can anyone give me an update on Juvenescence as we are coming up to the 2 year announcement anniversary, are they about to market our product? Will we see royalties start to come through?
Why is there nothing but sells here.
Any thoughts on today’s mega trade !!!
Looks like big seller getting itchy !
The price is probably getting close to Kight topping up again.
Have you tried reading news releases, watching the recent Youtube video etc, or maybe contacting the company directly? Might be more fruitful than asking on here?
Say what you like about the current market one thing is for sure and that is the trend here is down for about the last 2 years. Soon there will be no trend because it will reach its final destination and resting place.
What are management up to if anything ?
Thank you I just hope your hope is justified.
@Radar…..in case you hadn’t noticed the whole market has been getting a kicking in last few months……..anyway, this Company remains mostly under the “radar” pardon the pun….some ongoing patience is needed.
You just need to study about the great potential for sulforaphane based medicines and digest what is being outlined in the full year results RNS and recent proactive interview with CEO and you should be able to recognise that EVG has plenty going for it with some excellent ongoing JV / collaborations in place and is actively targeting to expand upon them. They are scheduled to move from planning stage into commencing several key medical trials at the backend of this year. The rollout of their health market product line (does not rely on medical approvals) via the Juvlife partnership is now scheduled for H2 2023 (likely got shifted from this year due to covid impact). They have no issues with short/medium term funds with 9 MillionGBP cash available as at 31/3/22., which pretty much equates to their current market cap. I personally see this as a good risk/reward opportunity going forward compared to most peers in the pharma sector.
Do any of the well informed and intelligent investors here see ant prospect of a reversal in fortune here in the forces Le future because for the past 3 years the performance has been pathetic.
Excellent interview - nice to see Huw coming across as a bit more dynamic than in his usual interviews.
Looks like this is on target to fall off the market !
Working now
Anyone else see 'this video is private'?
Encouraging news imo.
A big pharma buy in via a JV would be better still.
JuvLife partnership around the application of the Sulforadex® technology continues to progress well; US market launch of a JuvLife nutritional health product is anticipated around end- 2023They seem to be pushing this further and further down the road. I'm sure when it was first announced the payment was due in 2022.